Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection

Amber L Beitelshees¹, James M Stevenson², Nihal El Rouby^{3

4}, Chrisly Dillon⁵, Philip E Empey², Elliot M Fielstein⁶, Julie A Johnson³, Nita A Limdi⁵, Henry H Ong⁷, Francesco Franchi⁸, Dominick J Angiolillo⁸, Joshua F Peterson⁶, Marc B Rosenman⁹, Todd C Skaar¹⁰, Sony Tuteja¹¹, Larisa H Cavallari³; IGNITE Pharmacogenetics Working Group

Affiliations

¹ University of Maryland School of Medicine, Department of Medicine and Program for Personalized and Genomic Medicine, Baltimore, MD, USA. abeitels@som.umaryland.edu.
² University of Pittsburgh School of Pharmacy, Department of Pharmacy and Therapeutics, Pittsburgh, PA, USA.
³ University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, Gainesville, FL, USA.
⁴ University of Cincinnati James L. Winkle College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences, Cincinnati, OH, USA.
⁵ University of Alabama at Birmingham and Hugh Kaul Precision Medicine Institute, Birmingham, AL, USA.
⁶ Department of Biomedical Informatics and Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁷ Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
⁸ University of Florida College of Medicine, Department of Medicine, Division of Cardiology, Jacksonville, FL, USA.
⁹ Indiana University School of Medicine, Department of Pediatrics, Indianapolis, IN, and Ann & Robert H. Lurie Children's Hospital of Chicago, and Northwestern University, Chicago, IL, USA.
¹⁰ Indiana University School of Medicine, Department of Medicine, Indianapolis, IN, USA.
¹¹ University of Pennsylvania Perelman School of Medicine, Department of Medicine, Division of Translational Medicine and Human Genetics, Philadelphia, PA, USA.

PMID: 32747766
DOI: 10.1038/s41436-020-0931-1

Free article

Published Erratum

Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection

Amber L Beitelshees et al. Genet Med. 2020 Nov.

Free article

. 2020 Nov;22(11):1919.

doi: 10.1038/s41436-020-0931-1.

Authors

Affiliations

¹ University of Maryland School of Medicine, Department of Medicine and Program for Personalized and Genomic Medicine, Baltimore, MD, USA. abeitels@som.umaryland.edu.
² University of Pittsburgh School of Pharmacy, Department of Pharmacy and Therapeutics, Pittsburgh, PA, USA.
³ University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, Gainesville, FL, USA.
⁴ University of Cincinnati James L. Winkle College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences, Cincinnati, OH, USA.
⁵ University of Alabama at Birmingham and Hugh Kaul Precision Medicine Institute, Birmingham, AL, USA.
⁶ Department of Biomedical Informatics and Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁷ Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
⁸ University of Florida College of Medicine, Department of Medicine, Division of Cardiology, Jacksonville, FL, USA.
⁹ Indiana University School of Medicine, Department of Pediatrics, Indianapolis, IN, and Ann & Robert H. Lurie Children's Hospital of Chicago, and Northwestern University, Chicago, IL, USA.
¹⁰ Indiana University School of Medicine, Department of Medicine, Indianapolis, IN, USA.
¹¹ University of Pennsylvania Perelman School of Medicine, Department of Medicine, Division of Translational Medicine and Human Genetics, Philadelphia, PA, USA.

PMID: 32747766
DOI: 10.1038/s41436-020-0931-1

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

PubMed Disclaimer

Erratum for

Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Beitelshees AL, Stevenson JM, El Rouby N, Dillon C, Empey PE, Fielstein EM, Johnson JA, Limdi NA, Ong HH, Franchi F, Angiolillo DJ, Peterson JF, Rosenman MB, Skaar TC, Tuteja S, Cavallari LH; IGNITE Pharmacogenetics Working Group. Beitelshees AL, et al. Genet Med. 2020 Nov;22(11):1898-1902. doi: 10.1038/s41436-020-0894-2. Epub 2020 Jul 17. Genet Med. 2020. PMID: 32678355 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection

Affiliations

Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection

Authors

Affiliations

Abstract

Erratum for

Publication types

LinkOut - more resources

Full Text Sources